ROCKVILLE, Md., Oct. 5, 2023
/PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced
it will participate in the Jefferies CNS/Neuro Summit on
Thursday, October 12, 2023.
Jefferies CNS/Neuro Summit
Presentation Date:
Thursday, October 12, 2023
Presentation Time: 2:00 p.m.
ET
Location: New York, NY
A live webcast of the presentation can be accessed in the
Investors section of REGENXBIO's website at www.regenxbio.com. An
archived replay of the webcast will be available for approximately
30 days following the presentation.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. REGENXBIO's NAV Technology Platform, a proprietary
adeno-associated virus (AAV) gene delivery platform, consists of
exclusive rights to more than 100 novel AAV vectors, including
AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV
Technology Platform Licensees are applying the NAV Technology
Platform in the development of a broad pipeline of candidates,
including late-stage and commercial programs, in multiple
therapeutic areas. REGENXBIO is committed to a "5x'25" strategy to
progress five AAV Therapeutics from our internal pipeline and
licensed programs into pivotal-stage or commercial products by
2025.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
Chris Brinzey, ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-the-jefferies-cnsneuro-summit-301947963.html
SOURCE REGENXBIO Inc.